Rituximab

MedicationExperimental0 reviews

—

Average score out of 5

Experimental — This treatment is under research. Available data is limited. Consult your doctor before making any decision.

Rituximab is a monoclonal antibody that targets and depletes B cells. It is being investigated in Long COVID for its potential to eliminate autoantibodies and persistent B-cell activation that may contribute to symptoms.

Brand names

MabTheraRituxan

Information

Subcategory: anti-CD20 monoclonal antibody
Evidence level: 2/5
Evidence type: case reports and mechanistic rationale

Share your experience

Your feedback helps thousands of people find what really works.

Join the community